107 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author신인철-
dc.date.accessioned2018-03-23T01:52:20Z-
dc.date.available2018-03-23T01:52:20Z-
dc.date.issued2012-12-
dc.identifier.citationBMC Cancer, Dec 2012, 12(1), P.585en_US
dc.identifier.issn1471-2407-
dc.identifier.urihttps://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-585-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/51022-
dc.description.abstractBackground: The clinical implication of Ras/Raf/ERK pathway activity in breast cancer tissue and its association with response to chemotherapy is controversial. We aimed to explore the value of p90RSK phosphorylation, a downstram molecule of the pathway, in predicting chemotherapy response in breast cancer. Methods: The expression of phosphorylated p90RSK (phospho-p90RSK) and chemotherapy response was measured in 11 breast cancer cell lines and 21 breast cancer tissues. The predictive value of phospho-p90RSK was validated in core needle biopsy specimens of 112 locally advanced breast cancer patients who received anthracycline and taxane-based neoadjuvant chemotherapy. Results: In 11 breast cancer cell lines, the relative expression of phospho-p90RSK was inversely correlated with cell survival after doxorubicin treatment (p = 0.021). Similar association was observed in fresh tissues from 21 breast cancer patients in terms of clinical response. In paraffin-embedded, formalin-fixed tissues from core needle biopsy tissues from 112 patients, positive phospho-p90RSK expression was associated with greater tumor shrinkage and smaller post-chemotherapy tumor size. The association between phospho-p90RSK expression and chemotherapy response was more evident in estrogen receptor(ER)-positive tumors. The expression of phosphor-p90RSK did not show a significant relationship with the incidence of pCR. P90RSK silencing using siRNA did not affect the cancer cell's response to doxorubicin, and the expression of phospho-p90RSK was highly correlated with other Ras/Raf/ERK pathway activation. Conclusion: Our results suggest that phospho-p90RSK expression, which reflects the tumor's Ras/Raf/ERK/p90RSK pathway activation can be a potential predictive marker for chemotherapy response in ER-positive breast cancer which needs further independent validation.en_US
dc.description.sponsorshipThis study was supported by the the grant from the the National R&D Program (122020) for Cancer Control, Ministry of Health & Welfare, and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A2005929).en_US
dc.language.isoenen_US
dc.publisherBioMed Central Ltden_US
dc.subjectBreast canceren_US
dc.subjectP90RSKen_US
dc.subjectChemotherapyen_US
dc.subjectPredictive markeren_US
dc.subjectERKen_US
dc.subjectEstrogen receptoren_US
dc.titlePhosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast canceren_US
dc.typeArticleen_US
dc.relation.volume12-
dc.identifier.doi10.1186/1471-2407-12-585-
dc.relation.page1-2-
dc.relation.journalBMC CANCER-
dc.contributor.googleauthorMoon, HyeongGon-
dc.contributor.googleauthorYi, JaeKyo-
dc.contributor.googleauthorKim, HeeSung-
dc.contributor.googleauthorLee, HeaYoung-
dc.contributor.googleauthorLee, KyungMin-
dc.contributor.googleauthorYi, Minju-
dc.contributor.googleauthorAhn, Sookyung-
dc.contributor.googleauthorShin, HeeChul-
dc.contributor.googleauthorJu, Jihyun-
dc.contributor.googleauthorShin, Incheol-
dc.relation.code2012213039-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF NATURAL SCIENCES[S]-
dc.sector.departmentDEPARTMENT OF LIFE SCIENCE-
dc.identifier.pidincheol-
Appears in Collections:
COLLEGE OF NATURAL SCIENCES[S](자연과학대학) > LIFE SCIENCE(생명과학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE